Immunotherapies for locally aggressive cancers

Adv Drug Deliv Rev. 2024 Jul:210:115331. doi: 10.1016/j.addr.2024.115331. Epub 2024 May 8.

Abstract

Improving surgical resection outcomes for locally aggressive tumors is key to inducing durable locoregional disease control and preventing progression to metastatic disease. Macroscopically complete resection of the tumor is the standard of care for many cancers, including breast, ovarian, lung, sarcoma, and mesothelioma. Advancements in cancer diagnostics are increasing the number of surgically eligible cases through early detection. Thus, a unique opportunity arises to improve patient outcomes with decreased recurrence rates via intraoperative delivery treatments using local drug delivery strategies after the tumor has been resected. Of the current systemic treatments (e.g., chemotherapy, targeted therapies, and immunotherapies), immunotherapies are the latest approach to offer significant benefits. Intraoperative strategies benefit from direct access to the tumor microenvironment which improves drug uptake to the tumor and simultaneously minimizes the risk of drug entering healthy tissues thereby resulting in fewer or less toxic adverse events. We review the current state of immunotherapy development and discuss the opportunities that intraoperative treatment provides. We conclude by summarizing progress in current research, identifying areas for exploration, and discussing future prospects in sustained remission.

Keywords: Antibody; Biomaterials; CAR T; Cancer; Drug delivery; Hydrogel; Intraoperative; Mesothelioma; Nanoparticles; Non-small cell lung cancer; Sarcoma; Small Molecules.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Drug Delivery Systems
  • Humans
  • Immunotherapy* / methods
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Tumor Microenvironment / immunology